Updating the role of FDG PET/CT for evaluation of lung cancer manifesting in nonsolid nodules

Ying Liu; David F Yankelevitz; Lale Kostakoglu; Mary B Beasley; Yu Htwe; Mary M Salvatore; Rowena Yip; Claudia I Henschke

doi:10.1016/j.clinimag.2018.07.004

Updating the role of FDG PET/CT for evaluation of lung cancer manifesting in nonsolid nodules

Clin Imaging. 2018 Nov-Dec:52:157-162. doi: 10.1016/j.clinimag.2018.07.004. Epub 2018 Jul 6.

Authors

Ying Liu¹, David F Yankelevitz², Lale Kostakoglu³, Mary B Beasley⁴, Yu Htwe⁵, Mary M Salvatore⁶, Rowena Yip⁷, Claudia I Henschke⁸

Affiliations

¹ PET-CT Center, Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China.
² Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA. Electronic address: david.yankelevitz@mountsinai.org.
³ Department of Nuclear Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA. Electronic address: lale.kostakoglu@mountsinai.org.
⁴ Department of Pathology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA. Electronic address: mary.beasley@mountsinai.org.
⁵ Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois College of Medicine, 840 S Wood Street, Chicago, IL 60612, USA.
⁶ Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA. Electronic address: mary.salvatore@mountsinai.org.
⁷ Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA. Electronic address: rowena.yip@mountsinai.org.
⁸ Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA. Electronic address: claudia.henschke@mountsinai.org.

PMID: 30096553
DOI: 10.1016/j.clinimag.2018.07.004

Abstract

Purpose: To assess the feasibility of using CT to correct specific uptake values (SUVs) for fluorodeoxyglucose (FDG) in patients with nonsolid nodules.

Methods: Patients with FDG-PET/CT and thin-section CT were included in this pilot study. Thirty-five adenocarcinomas manifesting as nonsolid nodules were classified into two groups; 90-100% and 1-89% lepidic component. SUVmax was corrected based on the CT determination of the proportion of soft tissue component within the cancer (SUVatt).

Results: Both SUVmax and SUVatt increased as the percentage of the lepidic component decreased. SUVmax and SUVatt were significantly different between the groups.

Conclusion: Extent of invasiveness of nonsolid cancers (as a marker of aggressiveness) can potentially be quantified by PET/CT using a correction method that accounts for the proportion of soft tissue within the tumor.

Keywords: Adenocarcinoma; Ground-glass nodules; Lepidic component; Lung neoplasm; Standardized uptake values.

MeSH terms

Adenocarcinoma / diagnosis*
Aged
Female
Fluorodeoxyglucose F18 / pharmacology*
Humans
Lung Neoplasms / diagnosis*
Male
Pilot Projects
Positron Emission Tomography Computed Tomography / methods*
Radiopharmaceuticals / pharmacology

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18